Biotin IV Therapy: Mechanism, Evidence and Why the Route Adds Nothing

In short: biotin is a cofactor for a small set of carboxylase enzymes, and no trial has tested an intravenous biotin drip for hair or nails. The route argument collapses first — in a crossover study in six healthy adults, oral biotin at pharmacological doses was approximately 100% bioavailable against an intravenous reference, because at those doses absorption is passive and does not saturate. Genuine deficiency is uncommon on an ordinary diet: adequate intake is 30 µg/day in the United States and 40 µg/day under EFSA reference values, against a typical dietary supply of 35–70 µg/day. The hair literature is thin — a 2017 review found 18 published cases of improvement, all with an underlying pathology; the highest-quality controlled trial, from 1966, found no difference against placebo; a 2025 systematic review of ten studies found no consistent benefit from biotin monotherapy. The only large, rigorous trial of high-dose biotin in any indication, SPI2, gave 300 mg per day to 642 patients with progressive multiple sclerosis and missed its primary endpoint. And biotin carries a safety issue no drip menu mentions: it distorts immunoassays, the FDA has warned twice, and one death has been reported after falsely low troponin.

Biotin occupies an unusual position in infusion medicine. It is not contested in the way high-dose vitamin C or NAD are contested, because there is very little to contest — the trials that would generate an argument were mostly never run. What it has instead is an exceptionally clean answer to the one question the market builds its case on, and a documented safety problem that has nothing to do with toxicity.

What "biotin IV therapy" covers

Three quite different practices share the name. The first is therapeutic biotin for inherited disorders of biotin metabolism — biotinidase deficiency and holocarboxylase synthetase deficiency — where milligram doses given for life are the treatment and the response is unambiguous. This is a rare-disease indication, and it is oral.

The second is a licensed injectable that most of the market does not know exists. In France, Biotine Bayer 0.5% is authorised as a 5 mg per 1 mL solution for injection with the indication "adjunctive treatment of diffuse alopecia", dosed as one or two ampoules three times weekly for six weeks. Two details matter. The route on the label is intramuscular, not intravenous. And the indication is explicitly adjunctive, on an authorisation first granted in 1997; the product is not reimbursed.

The third is the hair-and-nail drip: biotin at multi-milligram doses in a multi-ingredient infusion alongside B vitamins, zinc and dexpanthenol, sold for hair growth, nail strength and skin quality in healthy adults. This is where the commercial interest sits, and it is the practice with no dedicated outcome trials of any kind.

Mechanism: a cofactor with a narrow job

Biotin is a water-soluble B vitamin that works as the prosthetic group of a small set of carboxylase enzymes — pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylase and 3-methylcrotonyl-CoA carboxylase. Each of those enzymes needs biotin covalently attached in order to move a carboxyl group: pyruvate to oxaloacetate in gluconeogenesis, acetyl-CoA to malonyl-CoA in fatty-acid synthesis, and two steps in the catabolism of odd-chain fatty acids and branched-chain amino acids. Biotinidase then recycles biotin from degraded carboxylases, which is why a defect in that enzyme produces deficiency despite normal intake.

That is the whole mechanism, and its narrowness is the point. Biotin is not a building block of hair. The hair shaft is keratin, a protein whose mechanical properties come from a high content of cysteine and the disulfide cross-links it forms. Supplying more biotin does not supply more keratin; it supports carboxylase reactions that are already running at capacity in a person with adequate intake. The dermatological signs of biotin deficiency — dermatitis and alopecia among them — are real, but they are the consequence of a metabolic block, not evidence that biotin is a growth stimulus above the point where the block disappears.

The route question, answered directly

Nearly every claim made for a biotin infusion rests on an absorption premise: oral supplements are said to be poorly and unreliably absorbed, so the vein is the reliable route. For most molecules this is a difficult claim to test cleanly. For biotin it has been tested, and the answer is unusually direct.

Six healthy adults received biotin orally at three doses — 2.1, 8.2 and 81.9 µmol — and intravenously at 18.4 µmol, in a crossover design with at least two weeks between administrations. The bioavailability of the two largest oral doses was approximately 100%. Not a majority, not a workable fraction: essentially the whole dose, measured against the intravenous route in the same subjects.

The mechanism behind that result explains why it should have been expected. Intestinal biotin uptake at dietary concentrations runs through the sodium-dependent multivitamin transporter, a carrier that saturates. At the milligram doses used in supplements, the carrier is long since saturated and biotin crosses the epithelium by passive diffusion, which does not saturate and is not regulated. The higher the dose, the more the passive route dominates — so precisely at the doses a drip would deliver, oral absorption is at its most complete.

This is the opposite of the situation with vitamin B12, where the route genuinely decides the answer because intrinsic-factor-mediated absorption is limited and saturable and the intravenous route is actively discouraged on the label. With biotin there is no gap to close in either direction. An infusion delivers what a capsule delivers, faster and at considerably greater cost, with a cannula and its attendant risks added.

Who is actually biotin deficient

Adequate intake is set at 30 µg per day in the United States and 40 µg per day in the EFSA dietary reference values, with the EFSA figure derived from observed intakes in the EU and the apparent absence of deficiency signs at those intakes. A typical mixed Western diet supplies roughly 35 to 70 µg per day. Against that background, clinically meaningful deficiency in someone eating normally is uncommon.

Where deficiency does occur, it has a cause that can be named: biotinidase or holocarboxylase synthetase deficiency; sustained consumption of raw egg white, whose avidin binds biotin and prevents absorption; long-term anticonvulsant therapy including carbamazepine, phenobarbital and valproate, which increase requirement; and some malabsorptive states. Marginal biotin status has also been described in pregnancy.

One figure circulates widely and deserves careful handling: a study reporting that roughly 38% of women presenting with hair loss were biotin deficient. It is real, and it is also the weakest kind of evidence to build a service on, because the methods used to define biotin deficiency are themselves contested and no biomarker is well standardised for routine use. Unlike carnitine or ferritin, biotin status is not a question a clinic can settle with a straightforward blood test — which means a biotin drip is almost always given without knowing whether the deficiency it is meant to correct exists.

What the hair evidence contains

The honest summary is that there is very little, and what there is points the wrong way for the marketing.

A 2017 review searched the literature for cases in which biotin was given and hair or nail growth improved. It found 18. In every one of them the patient had an underlying pathology that explained the poor growth, and most were paediatric — uncombable hair syndrome, brittle nail syndrome with an inherited metabolic defect, and similar. That is a coherent finding: biotin corrects a deficit where a deficit exists.

A 2024 review in the Journal of Clinical and Aesthetic Dermatology applied rigorous inclusion criteria and located three studies. The highest-quality of them, a double-blind placebo-controlled trial from 1966, found no difference between the biotin and placebo groups for hair growth. The other two examined niche populations — isotretinoin users and post-bariatric-surgery patients — and were not generalisable. The authors' conclusion is worth quoting because it is unqualified: "There have been no studies demonstrating biotin supplementation to be beneficial for hair growth in healthy individuals."

A 2025 systematic review following PRISMA methodology included ten human studies of biotin, alone or in combination, with hair outcomes. Biotin monotherapy did not show consistent benefit on objective hair-growth outcomes; where improvements were reported, they came from combined regimens, in which the contribution of biotin cannot be isolated. Many of the included studies carried at least moderate risk of bias from short follow-up, small samples and co-interventions.

Three independent reviews, three consistent answers. Note also what is absent from all of them: not one intravenous study. The evidence base being cited for a drip is an oral evidence base, and it is negative.

Nails: the two small studies behind the claim

The nail claim has a slightly better footing than the hair claim, and it is worth being precise about how much better. Two small studies from the early 1990s form its entire basis. A scanning electron microscopy study reported an approximately 25% increase in nail plate thickness in women taking 2.5 mg of biotin daily for at least six months. A second study in 35 adults with brittle nails, at the same 2.5 mg daily dose for six to nine months, reported clear clinical improvement in firmness and resistance to splitting in 63%.

Neither was placebo-controlled. The second was retrospective. Both used an oral dose of 2.5 mg daily sustained for six months or longer — a regimen that has nothing structurally in common with a single high-dose infusion, or a course of six weekly ones. If a clinic cites these studies for a nail drip, it is citing a six-month oral protocol as evidence for an intravenous one.

What happened when high dose was tested properly

Biotin has been through exactly one large, rigorous, placebo-controlled trial, and the result is instructive for anyone inclined to assume that a bigger dose would help.

High-dose pharmaceutical-grade biotin, MD1003 at 300 mg per day — roughly ten thousand times the adequate intake — showed a promising signal in progressive multiple sclerosis in an earlier phase 2b study, on the hypothesis that biotin-dependent carboxylases could support myelin repair and axonal energy metabolism. That signal justified a phase 3 trial. SPI2 randomised 642 patients across 90 academic and community clinics in 13 countries.

It missed. At the primary endpoint, 39 of 326 patients on MD1003 (12%) improved at month 12 with confirmation at month 15, against 29 of 316 on placebo (9%) — an odds ratio of 1.35, 95% CI 0.81 to 2.26. Neither disability nor walking speed improved significantly. The authors concluded that MD1003 cannot be recommended for the treatment of progressive multiple sclerosis. The trial also reported, despite the use of mitigation strategies, that MD1003 produced inaccurate laboratory results in tests using biotinylated antibodies — the same problem covered in the next section, observed under trial conditions with a protocol designed to prevent it.

This is the pattern this Journal has now documented in taurine, in glutamine and in cardiac carnitine: an encouraging early signal that does not survive an adequately powered trial. It is also the strongest available evidence on what very high doses of biotin do in humans, and what they do is not much.

The assay problem that is not on the menu

The clinically important risk of high-dose biotin is not toxicity. Biotin is water-soluble, no tolerable upper intake level has been established, and doses of 300 mg daily for months in the multiple sclerosis programme did not produce a characteristic toxicity syndrome. The risk is diagnostic.

A large proportion of modern immunoassays are built on the biotin–streptavidin binding pair, which is among the strongest non-covalent interactions in biology and is used to capture the analyte on a solid phase. Biotin circulating in a patient's blood competes for those binding sites. Depending on the assay architecture, the result comes out falsely high — as in some thyroid function tests, where the pattern can mimic Graves' disease — or falsely low.

The FDA issued a safety communication on this in November 2017 and updated it in November 2019. Its specific concern is falsely low troponin, because troponin is the biomarker used to diagnose myocardial infarction, and a falsely low result can mean a missed heart attack. The agency has a report of one patient taking high levels of biotin who died following falsely low troponin results on an assay known to be subject to biotin interference. The FDA notes that supplements marketed for hair, skin and nails can contain up to 20 mg of biotin, more than 650 times the recommended allowance, and recommends that clinicians ask patients about biotin and communicate it to the laboratory.

Set that against the practice being described here. A hair-and-nail infusion delivers a large biotin dose intravenously, producing a higher and faster peak concentration than the same dose by mouth even where total exposure is equivalent — and it is typically given in a wellness setting that does not appear in a hospital record. A patient who presents with chest pain days later may not think to mention a vitamin drip. This is the one aspect of biotin infusions that a clinician genuinely needs to act on, and it is the one no drip menu mentions.

The rest of the hair-and-nail infusion

Biotin rarely travels alone. The other ingredients deserve the same discipline.

Dexpanthenol, the alcohol analogue of pantothenic acid and one of the B-complex vitamins, has a licensed injectable form — and its licensed indication is the prevention and treatment of paralytic ileus after abdominal surgery, dosed intramuscularly. The label goes further than silence on the intravenous route: it advises that dexpanthenol injection should not be administered directly into a vein. Its systemic hair indication does not exist; the evidence for panthenol in hair care is topical.

Pyridoxine carries an upper limit worth respecting. EFSA re-evaluated vitamin B6 in May 2023 and set a tolerable upper intake level of 12 mg per day for adults, down from the 25 mg per day set in 2000, with peripheral neuropathy as the critical effect on which the limit is based. High-dose B6 is not a benign filler in a repeated infusion course.

Zinc has the most interesting evidence of the group, and it is deficiency-dependent in the same way biotin is. Serum zinc is consistently lower in people with hair loss than in controls across observational studies, lowest in telogen effluvium and alopecia areata. Supplementation has helped in zinc-deficiency-related telogen effluvium. But the one double-blind placebo-controlled trial, using oral zinc sulphate in alopecia areata, raised serum zinc substantially and produced no therapeutic benefit. Low zinc in a group with hair loss is a correlation; correcting it in people who are not deficient is not a treatment. High-dose zinc also depletes copper, and copper deficiency itself causes hair changes and anaemia.

The most useful thing to say about a hair-and-nail drip is what it usually omits. Iron deficiency, assessed by ferritin, is the nutritional factor with the clearest relationship to diffuse hair shedding in women, and it is diagnosable with a routine test. Vitamin C materially increases absorption of non-haem iron, which is a real formulation rationale. Thyroid disease and vitamin B12 deficiency are also treatable causes of hair change — and an infusion of biotin, given without those tests, can make several of them harder to detect for days.

Clinical evidence graded by indication

Set out by indication, biotin's evidence is strong where a metabolic block exists, marginal for nails, and absent everywhere the market operates.

Dosing, route and safety

Therapeutic dosing in inherited biotin disorders is 5 to 20 mg daily, orally, for life. The French injectable is 5 mg intramuscularly, one or two ampoules three times weekly for six weeks, as an adjunct in diffuse alopecia. The nail studies used 2.5 mg orally daily for six to nine months. The multiple sclerosis programme used 300 mg daily orally, and failed. There is no established intravenous dose of biotin for hair, nails or skin, because there is no indication to dose against.

On safety, the honest position is that biotin is well tolerated and that no tolerable upper intake level has been set — not because high intakes have been demonstrated safe, but because the data were judged insufficient to establish one. The active risks are two. First and most important, assay interference: stop biotin before planned blood tests, tell the laboratory, and treat any implausible thyroid or troponin result in a supplement user as suspect until repeated on an interference-free platform. Second, the risks belonging to the infusion itself rather than the molecule — cannulation, infection, and the co-administered ingredients, particularly pyridoxine against a 12 mg per day upper limit and zinc against copper depletion.

How to read a hair-and-nail formulation

Three questions separate a defensible formulation from a marketing one. First, deficiency or optimisation — is there a documented cause of deficiency, or is the infusion treating an assumption? With biotin the honest answer is usually the latter, because status is difficult to measure reliably, which argues for humility rather than for higher doses. Second, route — is the cited evidence oral or intravenous? For biotin it is entirely oral, and the bioavailability data mean the intravenous route adds nothing but speed and cost. Third, claim — is the formulation described as supporting the metabolic pathways involved in keratin-forming tissue, or as growing hair? Only the first is supportable.

A concept built around biotin, dexpanthenol, pyridoxine and zinc, such as the Hair and Nail formulation in the IVIXIR series, is coherent as a nutrient-support composition: each component has a defined biochemical role in the tissues concerned, and the pairing of zinc with B vitamins is conventional. What the literature does not support is presenting that composition as a treatment for hair loss, or the intravenous route as an improvement on oral dosing. Keeping those apart — what a molecule does, what a route can deliver, and what a formulation has been shown to do — is the standard EFBA applies. Biotin makes the exercise unusually clear, because the two things most often claimed for it, superior absorption by vein and hair growth in healthy adults, are the two that have been tested and found wanting.